# Clinical trials recruiting in Washington: 1,752 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 1,752 trials recruiting or not yet recruiting with a site in Washington, as read on November 19, 2026.

## The full list

Clinical trials recruiting in Washington: 1,752 rows for $87.60, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 26 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/state/washington

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 1,752
- Recruiting or not yet: 1,752
- Read on: November 19, 2026

## Trials

The 25 newest of 1,752, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 18, 2026 | NCT07945821 | A Study of Tagmokitug in Combination With Other Treatments in Participants With Advanced or Metastatic Solid Tumors | Coherus Oncology, Inc. | Phase 1/2 | Recruiting | Solid Tumor | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07945821) |
| November 16, 2026 | NCT07939529 | People With Active Viremia Treated With Lenacapavir and Long-Acting Cabotegravir for Effectiveness | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 | Not yet recruiting | HIV Viremia | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07939529) |
| November 13, 2026 | NCT07936266 | Asciminib and Inotuzumab Ozogamicin for Relapsed or Refractory Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (R/R... | Sponsor not shown (see the record) | Phase 1 | Recruiting | B-cell Acute Lymphoblastic Leukemia (B-ALL) | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07936266) |
| November 12, 2026 | NCT07931690 | IMPACT-Ready Study | Sponsor not shown (see the record) | Observational | Not yet recruiting | Autism Spectrum Disorder, Neurodevelopmental Disorders | 1,250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07931690) |
| November 12, 2026 | NCT07931573 | AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to... | Novo Nordisk A/S | Phase 3 | Not yet recruiting | Type 2 Diabetes | 1,200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07931573) |
| November 10, 2026 | NCT07928245 | A Study of Brenipatide in Participants With Major Depressive Disorder | Eli Lilly and Company | Phase 2 | Not yet recruiting | Major Depressive Disorder | 330 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07928245) |
| November 10, 2026 | NCT07927413 | Effectiveness and Safety of TachoSil® Fibrin Sealant Patch for Supporting Dural Sealing Among Adult Inpatients | Corza Medical GmbH | Observational | Recruiting | Cerebrospinal Fluid (CSF) Leak, Psuedomeningocele | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07927413) |
| November 6, 2026 | NCT07922772 | Days-Off Versus Daily Initial Peritoneal Dialysis Prescription | University of Michigan | Not applicable | Not yet recruiting | Kidney Failure | 450 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07922772) |
| November 5, 2026 | NCT07919405 | A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and... | Novo Nordisk A/S | Phase 3 | Not yet recruiting | Hypertension, Obesity | 1,408 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07919405) |
| November 4, 2026 | NCT07915934 | Adapting the "Do More, Feel Better" Intervention for Older People Living With HIV | University of Washington | Not applicable | Not yet recruiting | Depression, HIV | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07915934) |
| November 4, 2026 | NCT07915219 | A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON) | Boehringer Ingelheim | Phase 3 | Not yet recruiting | Bronchiectasis | 1,500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07915219) |
| November 2, 2026 | NCT07910435 | Polatuzumab Vedotin, Mosunetuzumab, and Acalabrutinib for the Treatment of Mantle Cell Lymphoma, PAcMan Trial | University of Washington | Phase 2 | Not yet recruiting | Mantle Cell Lymphoma | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07910435) |
| November 2, 2026 | NCT07909005 | Long Term Safety Study in Patients With HLH/MAS in Still's Disease Exposed to Gamifant. | Swedish Orphan Biovitrum | Observational | Not yet recruiting | Hemophagocytic Lymphohistiocytosis (HLH), Macrophage Activation Syndrome (MAS), Still Disease | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07909005) |
| November 2, 2026 | NCT07908407 | Remote Screening and Navigation to Increase Trial Enrollment, INVITE Trial | Fred Hutchinson Cancer Center | Not applicable | Not yet recruiting | Bladder Carcinoma, Prostate Carcinoma | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07908407) |
| October 29, 2026 | NCT07905027 | A Study of CLEC2A CAR T for Pediatric and Adult Patients With Relapsed or Refractory AML | Seattle Children's Hospital | Phase 1 | Not yet recruiting | Acute Myeloid Leukemia, Acute Myeloid Leukaemia Recurrent, Acute Myeloid Leukaemia Refractory | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07905027) |
| October 29, 2026 | NCT07903675 | Effectiveness of the Autism Pupil Screen (APS) Detect Pupillometer for Identifying Autism Spectrum Disorder (ASD) in Routine Healthcare | Schweitzer Engineering Laboratories | Observational | Recruiting | Autism Spectrum Disorder | 330 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07903675) |
| October 28, 2026 | NCT07900633 | A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk | Eli Lilly and Company | Phase 3 | Not yet recruiting | Obesity, Overweight, Cardiovascular Diseases, Diabetes Mellitus, Type 2 | 3,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07900633) |
| October 28, 2026 | NCT07899983 | Effect of Povidone Iodine on the Dental Implant Internal Surface Microbiome | Madigan Army Medical Center | Phase 1/2 | Not yet recruiting | Dental Implant | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07899983) |
| October 27, 2026 | NCT07897370 | Cardiac Arrest - Ultrasound Detection of Occult Perfusion | University of Massachusetts, Worcester | Observational | Recruiting | Cardiac Arrest, Out-Of-Hospital, Hypotension | 1,400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07897370) |
| October 27, 2026 | NCT07896473 | Study Comparing Osteoarthritis Programs | Weill Medical College of Cornell University | Not applicable | Not yet recruiting | Osteoarthritis | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07896473) |
| October 22, 2026 | NCT07890610 | Physiology-directed Epinephrine Dosing in Pediatric Cardiac Arrest | Children's Hospital of Philadelphia | Observational | Recruiting | Cardiac Arrest (CA) | 1,620 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07890610) |
| October 22, 2026 | NCT07890376 | A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes | Eli Lilly and Company | Phase 2 | Not yet recruiting | Obesity, Overweight | 460 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07890376) |
| October 21, 2026 | NCT07887061 | Tacabrutideg and Sonrotoclax, With Response-Guided Obinutuzumab, for the Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic... | Fred Hutchinson Cancer Center | Phase 2 | Not yet recruiting | Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07887061) |
| October 19, 2026 | NCT07881809 | A Clinical Study of Ixazomib to Reactivate HIV and Reduce HIV Reservoir Size | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | Not yet recruiting | HIV (Human Immunodeficiency Virus) | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07881809) |
| October 19, 2026 | NCT07881458 | A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes | Eli Lilly and Company | Phase 3 | Recruiting | Obesity, Overweight, Diabetes Mellitus, Type 2 | 1,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07881458) |

## Sites with the most of these trials

Sites as the records name them, organizations only.

| Site | City | Trials |
| --- | --- | --- |
| Seattle Children's Hospital | Seattle | 181 |
| University of Washington | Seattle | 180 |
| Fred Hutchinson Cancer Center | Seattle | 157 |
| Fred Hutch/University of Washington Cancer Consortium | Seattle | 105 |
| Swedish Medical Center-First Hill | Seattle | 74 |
| Swedish Cancer Institute-Edmonds | Edmonds | 67 |
| Swedish Cancer Institute-Issaquah | Issaquah | 66 |
| University of Washington Medical Center | Seattle | 53 |
| PeaceHealth Saint Joseph Medical Center | Bellingham | 49 |
| Kadlec Clinic Hematology and Oncology | Kennewick | 49 |
| Swedish Cancer Institute | Seattle | 44 |
| Providence Regional Cancer Partnership | Everett | 44 |
| PeaceHealth Southwest Medical Center | Vancouver | 43 |
| Providence Saint Mary Regional Cancer Center | Walla Walla | 43 |
| Providence Regional Cancer System-Lacey | Lacey | 42 |
| Swedish Medical Center-Ballard Campus | Seattle | 42 |
| University of Washington Medical Center - Montlake | Seattle | 42 |
| PeaceHealth Saint John Medical Center | Longview | 41 |
| Swedish Medical Center-Cherry Hill | Seattle | 41 |
| PeaceHealth United General Medical Center | Sedro-Woolley | 41 |
| Fred Hutchinson Cancer Research Center | Seattle | 40 |
| Providence Regional Cancer System-Aberdeen | Aberdeen | 40 |
| Providence Regional Cancer System-Centralia | Centralia | 40 |
| Virginia Mason Medical Center | Seattle | 36 |
| Swedish Medical Center | Seattle | 36 |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 8 |
| Phase 1 | 135 |
| Phase 1/2 | 141 |
| Phase 2 | 357 |
| Phase 2/3 | 47 |
| Phase 3 | 483 |
| Phase 4 | 42 |
| Not applicable | 294 |
| Observational | 245 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Carcinoma, Non-Small-Cell Lung | 96 |
| Neoplasms | 63 |
| Prostatic Neoplasms | 62 |
| Breast Neoplasms | 57 |
| Colorectal Neoplasms | 53 |
| Neoplasm Metastasis | 52 |
| Lung Neoplasms | 48 |
| Leukemia, Myeloid, Acute | 43 |
| Ovarian Neoplasms | 39 |
| Obesity | 38 |
| Multiple Myeloma | 34 |
| Urinary Bladder Neoplasms | 31 |
| Pancreatic Neoplasms | 30 |
| Endometrial Neoplasms | 30 |
| Recurrence | 30 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 29 |
| Melanoma | 29 |
| Overweight | 28 |
| Heart Failure | 28 |
| Diabetes Mellitus, Type 2 | 26 |
| Myelodysplastic Syndromes | 24 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 24 |
| Depressive Disorder, Major | 22 |
| Hematologic Neoplasms | 22 |
| Lymphoma, Follicular | 22 |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| University of Washington | 143 |
| Fred Hutchinson Cancer Center | 69 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 55 |
| National Cancer Institute (NCI) | 50 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 50 |
| Seattle Children's Hospital | 31 |
| [Bristol-Myers Squibb](https://specstream.ai/data/clinical-trials/company/bristol-myers-squibb) | 29 |
| [Merck Sharp & Dohme LLC](https://specstream.ai/data/clinical-trials/company/merck-sharp-and-dohme-llc) | 29 |
| [Janssen Research & Development, LLC](https://specstream.ai/data/clinical-trials/company/janssen-research-and-development-llc) | 26 |
| [AbbVie](https://specstream.ai/data/clinical-trials/company/abbvie) | 26 |
| VA Office of Research and Development | 25 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 25 |
| Children's Oncology Group | 25 |
| SWOG Cancer Research Network | 21 |
| [Novartis Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/novartis-pharmaceuticals) | 21 |
| Alliance for Clinical Trials in Oncology | 18 |
| [Novo Nordisk A/S](https://specstream.ai/data/clinical-trials/company/novo-nordisk-a-s) | 17 |
| [Amgen](https://specstream.ai/data/clinical-trials/company/amgen) | 16 |
| [Sanofi](https://specstream.ai/data/clinical-trials/company/sanofi) | 16 |
| [GlaxoSmithKline](https://specstream.ai/data/clinical-trials/company/glaxosmithkline) | 15 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 14 |
| [Regeneron Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/regeneron-pharmaceuticals) | 13 |
| [Hoffmann-La Roche](https://specstream.ai/data/clinical-trials/company/hoffmann-la-roche) | 13 |
| [BeOne Medicines](https://specstream.ai/data/clinical-trials/company/beone-medicines) | 13 |
| Washington State University | 12 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in Washington

- [Sheet metal fabricators in Washington, United States](https://specstream.ai/data/businesses/sheet-metal-fabricators/washington-united-states)
- [Surgery practices in Washington, United States](https://specstream.ai/data/businesses/surgery-practices/washington-united-states)
- [Tiling contractors in Washington, United States](https://specstream.ai/data/businesses/tiling-contractors/washington-united-states)
- [Warehouses in Washington, United States](https://specstream.ai/data/businesses/warehouses/washington-united-states)
- [Acupuncture clinics in Washington, United States](https://specstream.ai/data/businesses/acupuncture-clinics/washington-united-states)
- [Asian restaurants in Washington, United States](https://specstream.ai/data/businesses/asian-restaurants/washington-united-states)
